Beam Therapeutics Inc. (BEAM) 8-K Current Report: February 24, 2026
Filed: February 24, 2026
Health Care
Biological Products, (No Diagnostic Substances)Beam Therapeutics Inc. (BEAM) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 2.02: Results of Operations and Financial Condition
Beam Therapeutics Inc. 8-K Feb 24, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • $500M senior secured term loan from Sixth Street; only $100M drawn at close, remaining $400M milestone-gated on FDA BLA acceptance, approval, and risto-cel revenue targets
- • Interest rate: 3-month SOFR + 6.50% (1.00% floor), interest-only quarterly payments with full principal bullet due Feb 2033
- • Collateral: first-priority lien on substantially all assets including IP — meaningful encumbrance on Beam's core base-editing technology portfolio
- • Liquidity covenant triggers if market cap falls below $1.75B: minimum cash floors scale from $40M → $80M → $125M as additional tranches are drawn
- • Convertible note cap set at $400M outstanding — limits near-term dilutive financing flexibility while restricting M&A, asset sales, and additional debt
Item 2.02 · Results of Operations and Financial Condition
- • Q4 2025 earnings reported Feb 24, 2026 — full results in Exhibit 99.1 press release
- • BEAM is a clinical-stage gene editing company; revenue/burn rate and cash runway are key investor metrics to track in the release
Other Beam Therapeutics Inc. 8-K Filings
Get deeper insights on Beam Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.